Ascendis Pharma Files 6-K, Incorporates into S-8 Filings
Ticker: ASND · Form: 6-K · Filed: Jun 9, 2025 · CIK: 1612042
Sentiment: neutral
Topics: reporting, registration, employee-stock-plans
TL;DR
Ascendis Pharma (ASND) filed a 6-K, mostly for employee stock plan registrations. Business as usual.
AI Summary
Ascendis Pharma A/S filed a Form 6-K on June 9, 2025, to report information as a foreign private issuer. This filing is incorporated by reference into several of its Form S-8 registration statements, which are used for employee stock plans. The company is based in Hellerup, Denmark, and operates in the pharmaceutical preparations industry.
Why It Matters
This filing indicates ongoing administrative and reporting activities for Ascendis Pharma's employee stock incentive plans, suggesting continued operational management and compliance.
Risk Assessment
Risk Level: low — This filing is primarily administrative and does not appear to contain new material financial or operational information that would significantly alter risk.
Key Players & Entities
- Ascendis Pharma A/S (company) — Registrant
- 001-36815 (company) — SEC File Number
- 333-203040 (company) — Form S-8 Registration Number
- 333-210810 (company) — Form S-8 Registration Number
- 333-211512 (company) — Form S-8 Registration Number
- 333-213412 (company) — Form S-8 Registration Number
- 333-214843 (company) — Form S-8 Registration Number
- 333-216883 (company) — Form S-8 Registration Number
- 333-228576 (company) — Form S-8 Registration Number
FAQ
What is the purpose of this Form 6-K filing by Ascendis Pharma A/S?
The Form 6-K is filed by Ascendis Pharma A/S as a report of a foreign private issuer and is incorporated by reference into several of its Form S-8 registration statements.
When was this Form 6-K filed?
This Form 6-K was filed on June 9, 2025.
What is the principal executive office address for Ascendis Pharma A/S?
The principal executive offices are located at Tuborg Boulevard 12, DK-2900 Hellerup, Denmark.
Which SEC Act does this filing fall under?
This filing is made pursuant to Section 13a-16 or 15d-16 under the Securities Exchange Act of 1934.
What type of registration statements are being referenced in this filing?
This filing is incorporated by reference into Ascendis Pharma A/S's registration statements on Form S-8.
Filing Details
This Form 6-K (Form 6-K) was filed with the SEC on June 9, 2025 regarding Ascendis Pharma A/S (ASND).